The coexistence of both Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis (BE) define an emerging phenotype with a worse prognosis; however, data about these patients do not consider baseline characteristics as confounders. We evaluate the impact of BE on outcomes of hospitalized patients with acute exacerbation of COPD (AECOPD). We prospectively considered AECOPD patients, analysed using a propensity score matching (PSM) method. The outcomes included length of hospital stay, use of non-invasive and invasive mechanical ventilation, intensive care unit admission, and mortality up to 3-years. Out of the 449 patients enrolled, 160 had associated BE. AECOPD with BE were older, had lower body mass index and greater functional impairment and severity of symptoms than AECOPD without BE. After PSM, 91 patients were considered for each group and no significant differences were found for all baseline characteristics. In full cohort, the cumulative mortality rate, the survival time, the Kaplan-Meier survival curves and the risk of death were worse in AECOPD with BE in the follow-up of 6-months, 1-year and 3-years. After PSM, data on mortality were similar between AECOPD with and without BE. In conclusion, in AECOPD patients the presence of BE does not influence mortality in a long-term follow-up.
1
. During the natural course of COPD many patients experience acute exacerbation (AECOPD) characterized by a deterioration of respiratory signs and symptoms 2 and an increase of inflammatory response 3 . Bronchiectasis (BE) is a chronic respiratory condition related to a dilatation of bronchi and airway wall thickening on imaging of chest computed tomography (CT) scan 4 ; this irreversible alteration may lead to recurrent episodes of bronchial infections, inflammation, airway obstruction and progressive lung destruction 5 . In order to define the risk stratification of COPD patients 6 , specific risk factors (age 7 , smoking 8 , sex 9 ), clinical phenotypes (frequent exacerbators 10 , low body mass index-BMI 11 , increased dyspnoea 12 ), and measurements of disease severity (forced expiratory volume in the 1 st second-FEV 1 13 ) are associated to worse prognosis. For this reason, these measured baseline characteristics (covariates) may be considered as predictors of mortality [7] [8] [9] [10] [11] [12] [13] . At present, COPD is not considered a cause of BE and patients who fulfil both diagnostic criteria may be identified in an overlap condition 14 having a prevalence between 27% and 69% 4, [15] [16] [17] [18] . Although the presence of BE has been reported as an unfavourable feature for COPD 15, 17, [19] [20] [21] , the role of the baseline covariates [7] [8] [9] [10] [11] [12] [13] that are different between COPD patients with and without BE 16, 17, 22 have been not entirely evaluated. Although the mortality risk of BE in COPD patients has been evaluated with regression adjustment 15, 17, 18, 20 , residual confounding factors by unmeasured or inadequately measured baseline covariates may account for the rest of the risk. Comparability between groups should be a requirement in observational studies, avoiding indication bias, a specific type of selection bias 23 ; the use of restriction may minimize bias 23, 24 . Propensity score (PS) 25 represents the estimated probability of exposure assignment conditional on observed baseline covariates. Propensity score matching (PSM) matches patients in each group based on the similarity of their PS and the distribution of observed baseline covariates will be similar between exposed and unexposed subjects, reducing the effect of confounding variables 26 . Our study hypothesis was that potential baseline covariates may influence the clinical impact and prognosis of hospitalized AECOPD patients with BE in a short and long-term follow-up. Using a PSM method and eliminating baseline differences between AECOPD patients with and without BE, we could evaluate the impact of BE that is still lacking in AECOPD patients.
Methods
Study Design. This was a prospective study conducted at the Hospital Clinic of Barcelona (Spain) in a period of 7 years between May 2009 and May 2016. The sampling method was systematic and all AECOPD patients admitted to our Pneumology Department were enrolled in the study.
Patients Selection. The patients included had to meet COPD criteria according to the GOLD document 27 . Spirometry was performed in the stable phase and at least six months prior admission to hospital and a smoking history of 20 pack/years was considered as a positive habit. Definition of AECOPD was based on worsening of respiratory symptoms compared with preceding days requiring a change in domiciliary therapy 27 ; the hospitalization was based on the severity of AECOPD according to the respiratory signs or symptoms and the presence of potential indicators 27 . The presence of BE was detected by a chest CT scan, performed during hospitalization or in a period of at least six months before hospital admission. The radiological features of BE collected regards type (cylindrical, cystic or both), distribution (upper, middle or lower lobes or associated lobes), position (lung right, left or bilateral), and extension (or ≥3 involved lobes). Patients without a chest CT scan available were classified as AECOPD without BE.
Exclusion Criteria. The exclusion criteria concerned patients with a documented history of other concomitant chronic respiratory disease (asthma, cystic fibrosis) and patients in whom a community-acquired pneumonia or an acute heart failure were identified clinically and by chest X-ray or CT scan at admission. 
Microbiological Sample collection.
On the first day of hospitalization sputum sample was collected from spontaneous cough; if the sample was adequate (a count of more than 25 leukocytes and less than 10 epithelial cells per field) it was processed using Gram stain and sputum culture. In patients without a spontaneous sputum sample an induced sputum production was obtained by an inhalation of a 5% hypertonic saline solution for 5 to 10 minutes delivered via a nebulizer device.
Measurements. Data about demographic variables, body mass index (BMI), smoking habit (current or former) with number of pack/year, number of comorbidities (Charlson index), prevalence of ischemic heart disease and diabetes, dyspnea grade measured by the modified Medical Research Council (mMRC) scale, severity of disease (COPD severity score measured by a COPD-SS questionnaire), and use of long-term oxygen therapy (LTOT) were recorded. Season of occurrence of AECOPD, characteristics and number of previous AECOPD occurring in the preceding year and data on home care medications (inhaled bronchodilators as short-acting β 2 agonist [SABA], long-acting β 2 agonist [LABA], anticholinergics, inhaled steroids [ICS]) were also recorded.
Vital signs (body temperature, respiratory and heart rate, systolic and diastolic blood pressure) were assessed at admission. At admission and at day 3 we recorded data about gas analysis (pH, partial arterial carbon dioxide pressure [PaCO 2 ], the ratio of partial arterial oxygen pressure to the fraction of inspired oxygen [PaO 2 /FiO 2 ], serum bicarbonate [HCO 3 − ], and base excess [BE]), systemic response (leukocytes, haematocrit, haemoglobin, C-reactive protein [CRP] , glucose, and creatinine). Data on number of patients using systemic corticosteroids and/or antibiotics, duration of antibiotic treatment and classes of antibiotics used were also recorded.
Outcomes. Length of hospital stay (LOS), use of non-invasive and invasive mechanical ventilation (NIMV and IMV), and intensive care unit (ICU) admission were considered as variables of clinical progression. Data on prognosis (cumulative number of deaths for all-causes, estimated time to death) were recorded in a follow-up of 30 days, 6 months, 1 year and 3 years. The date of death was identified by centralized registries.
Statistical analysis.
A total sample size of 182 patients (91 patients in the group of AECOPD with BE and 91 patients in the group of AECOPD without BE, according to 1:1 allocation ratio) was estimated to provide at least a 80% power and a two-sided alpha value of 0.05 to detect as statistically significant an absolute difference of 15% in the percentage of 3-years mortality of patients between groups (20% patients with BE vs 5% patients without BE) 17 . Data were reported with number and percentage of patients for categorical variables, means ± standard deviation (SD) or medians [ PS was used to obtain the balance among baseline variables between AECOPD patients with and without BE listed in Table 1 . A PSM program 28 was used to match the two cohorts using a 1:1 nearest neighbour matching, without replacement within a caliper width of 0.2. Variables were chosen for inclusion in the PS calculation according to the methods of Brookhart et al. 29 and included variables associated with hospitalized AECOPD patients with BE and outcome (age, BMI, FEV 1 , smoking habit, COPD-SS questionnaire, chest CT scan, and patients with ≥2 previous AECOPD). After matching, an adequate comparability was shown by a decrease to <20% (0.2) of the standardized mean difference 30 between AECOPD with and without BE for all baseline covariates (Fig. 1) ; moreover, an adequate model fit with discrimination and calibration of the PS was demonstrated by the logistic model including covariates yielded a Goodness-of-Fit p = 0.321.
Time-to event variables were analysed by means of Kaplan-Meier survival curves and a Gehan-Breslow-Wilcoxon test was applied because this test emphasizes early differences 31 . Patients lost to follow-up were censored in the survival analysis. Cox proportional hazard regression models were used in mortality at 30-days, 6-months, 1-year, and 3-years 32 . The hazard ratio (HR) and its 95% confidence intervals (CI) were calculated.
All statistical analyses were performed using IBM SPSS Statistics 24.0 (Armonk, New York, USA). A value of p < 0.05 was considered statistically significant. 1 , forced expiratory volume in the 1 st second; FVC, forced vital capacity; GOLD, global initiative for chronic obstructive lung disease; LTOT, long-term oxygen therapy; mMRC, modified Medical Research Council; COPD-SS, COPD severity score questionnaire; LABA, long-acting β 2 agonist; ICS, inhaled corticosteroids. LABA includes salmeterol, formoterol and indacaterol; Anticholinergic includes ipratropium and tiotropium; and ICS includes budesonide and fluticasone. *The variables included as covariates in the propensity score matching were: age, body mass index, forced expiratory volume in the 1 st second; smoking habit, COPD-SS severity questionnaire, chest CT scan, and patients with ≥2 previous AECOPD. † Previous AECOPD were considered if occurring in a period of the preceding year. 
Results
Baseline characteristics. 449 consecutive AECOPD patients (81% men) with a mean age of 72 years were considered; of these, 160 patients (36%) had associated BE. The chest CT scan was available in 330 patients (73%); in the PSM sample only patients having a chest CT scan (n = 182) were considered. Figure 2 shows the study flow diagram.
In full cohort, AECOPD patients with BE were older, with a lower BMI and greater functional impairment, severity of symptoms and questionnaire-reported severity characteristics than AECOPD patients without BE. Moreover, patients with BE were more frequently former smokers, with need for LTOT and had a significant history of AECOPD in the previous year, also requiring hospitalization. After PSM, no significant differences were found in all baseline characteristics (see Table 1 ).
Concerning the radiological aspects of BE, the cylindrical type (circle A) with a distribution in the lower lobes (circle B), in a bilateral position (circle C) and involving ≤3 lobes (circle D) represent the most prevalent features (86%, 41%, 77%, and 61%, respectively) (Fig. 3) .
Clinical, laboratory and microbiological variables. With regard to clinical and laboratory variables (Table 2) , AECOPD patients with BE in comparison to patients without BE showed a higher C-reactive protein (CRP) level at day 3 (median 1.7 mg/dL vs 0.9 mg/dL, p = 0.026) in full cohort. In the PSM cohort, at admission lower levels of PaCO 2 In full cohort, a greater prevalence of Pseudomonas aeruginosa (38% vs 19%, p = 0.037) and a lower prevalence of Haemophilus influenzae (8% vs 24%, p = 0.049) were shown in AECOPD patients with BE in comparison to patients without BE; after matching, all microbiological variables were similar between groups (Table 3) .
Outcomes. In the full cohort, AECOPD with BE in comparison to patients without BE showed a lower prevalence of NIMV (15% vs 25%, p = 0.011) and ICU admission (7% vs 15%, p = 0.016); the PSM cohort confirm data about lower prevalence of ICU admission in AECOPD with BE (6% vs 14%, p = 0.047) ( Table 4) .
In full cohort, the cumulative mortality rate was significantly higher in AECOPD patients with BE in comparison to patients without BE in the follow-up of 6-months, 1-year and 3-years (17% vs 9%, p = 0.015; 27% vs 16%, p = 0.013; 51% vs 40%, p = 0.045; respectively). Moreover, the mean survival time was lower in AECOPD patients with BE (mean 163.9 days vs 170.5 days, p = 0.016 at 6-months; 304.2 days vs 328.1 days, p = 0.009 at 1-year; 766.8 days vs 852.1 days, p = 0.014 at 3-years) ( Table 4 ). The Kaplan-Meier survival curves (Fig. 4) showed an unfavourable role of AECOPD patients with BE (Gehan-Breslow-Wilcoxon test p = 0.011 in the follow-up of 3 years). In the follow-up of 6-months, 1-year and 3-years, Cox regression ( . After PSM, the mortality rate, the mean survival time, the Kaplan-Meier survival curves, and the risk of death were similar between AECOPD patients with and without BE ( Table 4 , Fig. 4 and Table 5 , respectively). Concerning the prevalence of radiological features of BE according to the outcomes (Fig. 5) , the only right position in comparison to only left and bilateral was respectively associated to a higher prevalence of NIMV (37%, 9% and 13%, p = 0.027) and survivors at 3-years (69%, 21% and 54%, p = 0.011). Data about type, distribution, and extension of BE had not influenced all outcomes.
In the comparison of baseline covariates between survivors and deaths (Table 6) , in full cohort, in the follow-up of 6-months, 1-year and 3-years, deaths were among significantly older patients, former smokers, patients with greater staging severity, needing LTOT, with a higher dyspnoea grade, a greater questionnaire-reported severity and a higher number of previous AECOPD also needing hospitalization. BMI, FEV 1 % predicted and Charlson index were respectively worse in deaths at the follow-up of 1-year and 3-years, while prevalence of male gender were higher at 3-year follow-up only. In the PSM cohort, the Charlson index was different among survivors and death in the follow-up of 1-year and 3-years, while age, GOLD 2017 stage, LTOT, mMRC, and COPD-SS questionnaire were different in the follow-up of 3-years. 
Discussion
The coexistence of both COPD and BE has been recently defined as an emerging phenotype of patients 14 who experience worse prognosis 15, 17, [19] [20] [21] ; however, data on these patients do not consider several baseline covariates as cofounders. Our prospective study, performed for the first time in hospitalized AECOPD patients and using a PSM method, demonstrated that the presence of BE does not worse the clinical impact at admission, the clinical progression, the rate and the risk of short and long-term mortality.
Prevalence and characteristics associated to BE. Although in literature a large prevalence of BE associated to COPD is reported 4,15-18 , our prevalence in AECOPD patients was slight higher (36% vs 27%) in comparison with COPD patients in whom a CT scan was performed to phenotype the heterogeneity of disease 4 . Recent data on distinctive clinical, functional and microbiological phenotypes of patients with BE have shown the prevalence of BE having COPD as the aetiology cause in a percentage of 11% 33 , lower than previous reports (17%) 34 . It is than clear that differences in prevalence of patients having COPD and BE depend on the respective population under consideration.
Baseline characteristics of our patients with BE were consistent with other reports on age 15, 17 , low BMI 15-17 , smoking habit 15 , severe obstruction 16, 17, 22 , greater dyspnoea 16, 17 , need for oxygen-therapy 17, 22 and previous exacerbation events 16, 17, 22 . Concerning our higher prevalence of Pseudomonas aeruginosa isolation in patients AECOPD with BE, previous studies on COPD in stable phase confirmed these data 4, [16] [17] [18] 22 . The presence of this pathogen, most frequently in severe patients and during exacerbations 35 , favours the hypothesis that potentially pathogenic microorganisms (PPM) -and Pseudomonas aeruginosa is one of the most important PPM -are responsible for the development of BE by an increase in chronic inflammation 36 . Surprisingly, the prevalence of Haemophilus influenzae in our cohort with a positive sputum culture (n = 16, 17%) was lower in comparison to AECOPD patients in general 37 , to BE patients 38 , and stable COPD patients 17 . However, this prevalence was similar after PSM (n = 6, 15%) with a similar trend between AECOPD patients with and without BE. A different pathogen detection or a previous use of antibiotics before admission (not collected in this study) may explain the difference in prevalence.
Clinical impact of BE at admission. To our knowledge, we have reported for the first time data on the impact of BE on clinical presentation of AECOPD patients. In clinical practice, it is common belief that BE patients especially if in association with an AECOPD may have a worse impact. However, our findings demonstrate that clinical and laboratory data of AECOPD with and without BE were similar, except for hypercapnia levels with renal compensation, that appear better in AECOPD with BE, as well the prevalence of ICU admission (Tables 2 and 4 ). Interestingly, also the early inflammatory profile of AECOPD with and without BE was similar. Although COPD patients may have different profiles in response to pneumonic and nonpneumonic exacerbations 39 , we demonstrated that the presence of BE in AECOPD does not induce a stronger early inflammatory response. Mortality related to BE. In patients with AECOPD several predictors of mortality have been identified in a short and long-term period 40 ; as well in our data (Table 6) , age, BMI, FEV 1 , and LTOT predict the worse prognosis of AECOPD 40 .
There are no published studies evaluating the risk of death based on the presence of BE during an AECOPD, while in COPD patients the association with BE have been reported with 15, 17, 19, 20 and without 18 an impact on mortality. However, studies reporting the worse prognosis, also considered for a recent meta-analysis 21 , concern preliminary data with very few enrolled patients 19 and studies considering patients with evident baseline covariates, including elderly patients 20 , patients with very severe lung functional impairment 19, 20 , and patients with chronic respiratory failure needing oxygen-therapy 20 . Moreover, the adjustments in regression analysis leading to more striking estimates supported the hypothesis that confounding cannot account for the result 15 ; the role of confounding should always be considered as a possible alternative storyline 41 . Historically, regression adjustment has been used more frequently than PS methods to account for differences in measured baseline characteristics between exposed and unexposed subjects. However, there are several reasons for preferring PS-based methods to regression-based methods for reducing the effects of confounding in observational studies. First, related to the occurrence of BE and baseline covariates to the outcome, it is simpler to determine whether the PS model rather the regression model has been adequately specified. Diagnostics for PS are based on comparing the distribution of measured baseline covariates, between AECOPD with and without BE in the PSM sample. Goodness-of-fit measures in regression models do not provide a test of whether the outcome model has been correctly specified. Furthermore, goodness-of-fit do not allow one to determine the degree to which the fitted regression model has successfully eliminated systematic differences between AECOPD patients with and without BE.
Second, similarly to a randomized controlled trial (RCT), the PS-based methods allow one to separate the design from the analysis of the study, without any reference to the outcome. However, when using regression adjustment, the outcome is always in sight, and the researcher is faced with the subtle temptation to continually modify the regression model until the desired association has been achieved 42 . Table 5 . Cox regression models evaluating the risk of all-causes death for AECOPD with BE. Abbreviations: AECOPD indicates acute exacerbation of COPD; BE, bronchiectasis; HR, hazard ratio; CI, confidence interval. Cox regression for 30-days mortality in the propensity score matching sample cannot compute because all cases are censored. Third, there may be increased flexibility when the occurrence of BE is more common than outcome (time-to-event in nature) 43 . When outcome is time-to-event in nature, prior research has suggested that at least 10 events should be observed for every covariate that is entered into a regression model 44, 45 . Thus, in some settings, insufficient outcomes may be observed to allow one to adequately adjust for all baseline variables that one would like to include in the regression model. Fourth, the PS method provides a better assessment of the degree of overlap between the distribution of baseline covariates, comparing the outcome between patients who have a similar distribution of observed baseline covariates. In a setting in which there is a strong separation between the two groups, the analyst may proceed with a regression-based analysis without being aware that the fitted regression model is interpolating between two distinct populations.
In conclusion, PS method allows one to transparently design and analyze our observational study. Table 6 . Comparison of baseline covariates between survivors and deaths, in the full cohort and in the propensity score matching sample, in the follow-up of 6-months, 1-year and 3-years. Data are shown as number of patients (percentage), means ± standard deviation or medians [1 st quartile; 3 rd quartile], unless otherwise stated. Percentages are calculated on non-missing data. For the full cohort data are calculated on survivors (n = 381, n = 333, and n = 208) and deaths (n = 51, n = 84 and n = 166) in the follow-up of 6-months, 1-year and 3-years, respectively. In the propensity score matching sample data are calculated on survivors (n = 163, n = 144, and n = 97) and deaths (n = 8, n = 18 and n = 52) in the follow-up of 6-months, 1-year and 3-years, respectively. In full cohort, the percentage of lost in AECOPD without and with BE groups was 4% and 4% (p > 0.999), 8% and 6% (p = 0.591), and 19% and 13% (p = 0.130) in the follow-up of 6-months, 1-year and 3-years, respectively. In the propensity score matching sample, the percentage of lost in AECOPD without and with BE groups was 8% and 4% (p = 0.536), 15% and 7% (p = 0.058), and 21% and 15% (p = 0.336) in the follow-up of 6-months, 1-year and 3-years, respectively. Abbreviations: BMI indicates body mass index; FEV 1 , forced expiratory volume in the 1 st second; GOLD, global initiative for chronic obstructive lung disease; LTOT, long-term oxygen therapy; mMRC, modified Medical Research Council; COPD-SS, COPD severity score questionnaire.
SCIEnTIFIC REPORTS | (2018) 8:9236 | DOI:10.1038/s41598-018-27680-y Strength and limitation. The originality of using data about AECOPD patients with BE, the prospective and consecutive nature of the data collection, the large cohort of the patients enrolled, the long-term follow-up, and the statistical method using a PSM are the major strengths of our research. There are however some limitations. First, our study was conducted at a single centre and in only one country; data from international centres are therefore necessary to confirm our findings. Second, we had not chest CT scans for all enrolled patients and we cannot exclude an under estimation of BE. However, in clinical practice at admission to hospital, in an AECOPD patient without a radiological (all patients enrolled had performed a chest X-ray) and a clinical suspicion of BE, the chest CT scan is not performed. We may reasonable hypothesize that really these patients were AECOPD without BE, as we have classified. Moreover, the presence of a chest CT scan has been used as a covariate for the PS model and then all patients considered in PSM cohort (with and without BE) had performed a chest CT scan; this have eliminated the hypothetical bias that patients performing a chest CT scan were worst patients. Finally, the analysis of data excluding patients without a chest CT scan in full cohort (data not shown), after matching of all baseline characteristics produce similar results; however, the total sample size was not adequate to demonstrate the study hypothesis (see statistical analysis). Third, we lack information about the cause of death; in COPD patients, however, the causes of death (respiratory, cardiovascular, others) are not significantly influenced by BE 17 .
In conclusion, our study supports the hypothesis that in AECOPD patients, the clinical impact and prognosis of BE is influenced by several baseline covariates. After matching, with the elimination of confounding, BE does not directly worsen the prognosis of patients in a period until 3-years.
